Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
1-methyl-1H-indole-5-sulfonyl chloride → 5-(3,4-Dimethoxyphenyl)-4,4-dimethyl-2-{1-[(1-methyl-1H-indol-5-yl)sulfonyl]piperidin-4-yl}-2,4-dihydro-3H-pyrazol-3-one
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | 1-methyl-1H-indole-5-sulfonyl chloride | HCID 18525751 | — |
| 반응물 | 5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-piperidin-4-yl-2,4-dihydro-3H-pyrazol-3-one hydrochloride | HCID 66616406 | — |
| 생성물 | 5-(3,4-Dimethoxyphenyl)-4,4-dimethyl-2-{1-[(1-methyl-1H-indol-5-yl)sulfonyl]piperidin-4-yl}-2,4-dihydro-3H-pyrazol-3-one | HCID 67364464 | — |
반응 단계
The title compound is prepared analogously as described for GP1 using 5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-(piperidin-4-yl)-2,4-dihydro-3H-pyrazol-3-one (compound B1) and 1-methyl-1H-indole-5-sulfonyl chloride as starting compounds. The crude product is purified by crystallization from EA and diethyl ether to yield the title compound.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US09340522B2 |
| 출처 데이터셋 | uspto-grants-2016_05 |
| ORD ID | ord-13500ae2e0bd4222bf1a9004c64e6842 |
| 출처 메모 | uspto-grants-2016_05 |